M2 protein - A proton channel of influenza A virus

Current Pharmaceutical Design

Volumn 13, Issue 31, 2007, Pages 3231-3235

  Betakova, Tatiana ^a  

^a INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Antivirals; Influenza virus; Ion channel; M2 protein

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; PROTEIN M2; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

AMINO ACID SEQUENCE; CELL MEMBRANE; CYTOPLASM; DRUG TARGETING; HUMAN; INFLUENZA; INFLUENZA VIRUS A; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; PROTON TRANSPORT; RECEPTOR BINDING; REVIEW; VIRUS ASSEMBLY; VIRUS GENOME; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; ANTIVIRAL AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; ION CHANNELS; VIRAL MATRIX PROTEINS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 36749000488     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782341295     Document Type: Review

References (74)

1. Webby RJ, Webster RG. Emergence of influenza A viruses. Philos Trans R Soc Lond B Biol Sci 2001; 356: 1817-28.
2. WHO Geneva, 2006, Weekly epidemiological record. 81: 249-60.
3. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992; 56: 152-79.
4. Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, Bacik I, et al. A novel influenza A virus mitochondrial protein that induces cell death. Nat Med 2001; 7(12): 1306-12.
5. Goto H, Kawaoka Y. A novel mechanism for the acquisition of virulence by a human influenza A virus. Proc Natl Acad Sci USA 1998; 95: 10224-8.
6. Whittaker G, Bui M, Helenius A. The role of nuclear import and export in influenza virus infection. Trends Cell Biol 1996; 6: 67-71.
7. Bui M, Wills EG, Helenius A, Whittaker GR. Role of the influenza virus M1 protein in nuclear export of viral ribonucleoproteins. J Virol 2000; 74: 1781-6.
8. Ruigrok RW. Structure of influenza A,B, and C viruses. In: Nicholson KG, Webster RG, Hay AJ Eds, Textbook of Influenza. Blackwell Science Ltd., Oxford, UK 1998; 29-42.
9. Ye Z, Liu T, Offringa DP, McInnis J, Lewandowski RA. Association of influenza virus matrix protein with ribonucleoproteins. J Virol 1999; 73: 7467-73.
10. Jennings PA, Finch JT, Winter G, Robertson JS. Does the higher order structure of the influenza virus ribonucleoprotein guide sequence rearrangements in influenza viral RNA? Cell 1983; 34: 619-27.
11. Martin-Benito J, Area E, Ortega J, Ilorca O, Valpuesta JM, Carrascosa JL, et al. Three-dimensional reconstruction of a recombinant influenza virus ribonucleoprotein particle. EMBO Rep 2001; 2: 313-7.
12. 1) promotes export and inhibits import. Cell 1991; 67: 117-30.
13. Paragas J, Talon J, O'Neill RE, Anderson DK, Garcia-Sastre A, Palese P. Influenza B and C virus NEP (NS2) proteins possess nuclear export activities. J Virol 2001; 75: 7375-83.
14. Sugrue RJ, Belshe RB, Hay AJ. Palmitoylation of the influenza A virus M2 protein. Virology 1990; 179: 51-6.
15. Ciampor F, Bayley PM, Nermut MV, Hirst EM, Sugrue RJ, Hay AJ. Evidence that the amantadine-induced, M2-mediated conversion of influenza A virus hemagglutinin to the low pH conformation occurs in an acidic trans Gotgi compartment. Virology 1992; 188: 14-24.
16. Ohuchi M, Cramer A, Vey M, Ohuchi R, Garten W, Klenk HD. Rescue of vector-expressed fowl plague virus hemagglutinin in biologically active form by acidotropic agents and coexpressed M2 protein. J Virol 1994; 68: 920-6.
17. Takeuchi K, Lamb RA. Influenza virus M2 protein ion channel activity stabilizes the native form of fowl plague virus hemagglutinin during intracellular transport. J Virol 1994; 68: 911-9.
18. Scheiffele P, Rietveld A, Wilk T, Simons K. Influenza viruses select ordered lipid domains during budding from the plasma membrane. J Biol Chem 1999; 274: 2038-44.
19. Leser GP, Lamb RA. Influenza virus assembly and budding in raft-derived microdomains: A quantitative analysis of the surface distribution of HA, NA and M2 proteins. Virology 2005; 342: 215-27.
20. Wagner R, Matrosovich M, Klenk HD. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 2002; 12: 159-66.
21. Heijne GV. The distribution of positively charged residues in bacterial inner membrane proteins correlates with the trans-membrane topology. EMBO J 1986; 5: 3021-7.
22. Pinto LH, Holsinger LJ, Lamb RA. Influenza A virus M2 protein has ani on channel activity. Cell 1992; 69: 517-28.
23. Chizhmakov IV, Geraghty FM, Ogden DC, Hayhurst A, Antoniou M, Hay AJ. Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells. J Physiol 1996; 494: 329-36.
24. Mould JA, Drury JE, Frings SM, Kaupp UB, Pekosz A, Lamb RA, et al. Permeation and activation of the M2 ion channel of influenza A virus. J Biol Chem 2000; 275: 31038-50.
25. Grambas S, Hay AJ. Maturation of influenza A virus hemagglutinin-estimates of die pH encountered during transport and its regulation by the M2 protein. Virology 1992; 190: 11-8.
26. Iwatsuki-Horimoto K, Horimoto T, Noda T, Kiso M, Maeda J, Watanabe S, et al. The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly. J Virol 2006; 80: 5233-40.
27. McCown MF, Pekosz A. Distinct domains of the influenza a virus m2 protein cytoplasmic tail mediate binding to the m1 protein and facilitate infectious virus production. J Virol 2006; 80: 8178-89.
28. Holsinger LJ, Shaughnessy MA, Micko A. Analysis of the post-translational modifications of the influenza virus M2 protein. J Virol 1995; 69: 1219-25.
29. Holsinger LJ, Lamb RA. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 1991; 183: 32-43.
30. Sugrue RJ, Hay AJ. Structural characteristics of the M2 protein of influenza A viruses: Evidence that it forms a tetrameric channel. Virology 1991; 180: 617-24.
31. Lamb RA, Zebedee SL, Richardson CD. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985; 40: 627-33.
32. Zebedee SL, Lamb RA. Influenza virus M2 protein: Monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988; 62: 2762-72.
33. Park EK, Castrucci MR, Portner A, Kawaoka Y. The M2 ectodomain is important for its incorporation into influenza A virions. J Virol 1998; 72: 2449-55.
34. Fiets W, Filette MD, Birket A, Neirynck S, Jou WM. A "universal" human influenza A vaccine. Virus Res 2004; 103: 173-6.
35. Liu WL, Li H, Chen YH. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol 2003; 35: 141-6.
36. Liu W, Zou P, Ding J, Lu Y, Chen YH. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes and Infection 2005; 7: 171-7.
37. deFilette M, Fiers W, Martens W, Birkett A, Ramne A, Lowenadler B, et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 2006; 24: 6597-601.
38. Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol 1993; 74: 143-6.
39. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: Weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004;172: 5598-605.
40. Eriksson AM, Schon KM, Lycke NY. The cholera toxin-derivated CTA-DD vaccine adjuvant administrated intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol 2004; 173: 3310-9.
41. Liu WL, Zou P, Chen YH. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A M2 protein could protect mice from lethal influenza a virus challenge. Immunol Lett 2004; 93: 131-6.
42. Mozdzanowska K, Feng JQ, Eid M, Kragol G, Cidic M, Otvos L Jr, et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003; 21: 2616-26.
43. Fan J, Liang XP, Horton MS, Perry HC, Citron MP, Heidecker GJ, et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22: 2993-3003.
44. Heinen PP, Rijsewijk FA, deBoer-Luijtze EA, Bainchi AT. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza a virus. J Gen Virol 2002; 83: 1851-9.
45. Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of influenza A virus M2 protein: Characterization of the amantadine block. J Virol 1993; 67: 5585-94.
46. Holsinger LJ, Nichani D, Pinto LH, Lamb RA. Influenza A virus M2 ion channel protein: A structure-function analysis. J Virol 1994; 68: 1551-63.
47. Wang C., Lamb RA, Pinto LH. Activation of the M2 ion channel of influenza virus: A role for the transmembrane domain histidine residue. Biophys J 1995; 69: 1363-71.
48. Shimbo K, Brassard DL, Lamb RA, Pinto LH. Ion selectivity and activation of the M2 ion channel of influenza virus. Biophys J 1996; 70: 1335-46.
49. Chizhmakov IV, Ogden DC, Geraghty FM, Hayhurst A, Skinner A, Betakova T, et al. Differences in the polarity of pH-induced changes in conductance of the M2 proton channels of two influenza viruses. J Physiol 2003; 546: 427-38.
50. Kovacs FA, Cross TA. Transmembrane four-helix bundle of influenza A M2 protein channel: Structural implications from helix tilt and orientation. Biophys J 1997; 73: 2511-7.
51. Kukol A, Adams PD, Rice LM, Brunger AT, Arkin TI. Experimentally based orientational refinement of membrane protein models: A structure for the Influenza A M2 H+ channel. J Mol Biol 1999; 286: 951-62.
52. Kovacs FA, Denny JK, Song Z, Quine JR, Cross TA. Helix tilt of the M2 transmembrane peptide from influenza A virus: An intrinsic property. J Mol Biol 2000; 295: 117-25.
53. Song Z, Kovacs FA, Wang J, Denny JK, Shekar SC, Quine JR, et al. Transmembrane domain of M2 protein from influenza A virus studied by solid-state (15)N polarization inversion spin exchange at magic angle NMR. Biophys J 2000; 79: 767-75.
54. Castrucci MR, Hughes M, Calzoletti L, Donatelli I, Wells K, Takada A, et al. The cysteine residues of the M2 protein are not required for influenza A virus replication. Virology 1997; 238: 128-34.
55. Pinto LH, Dieckmann GR, Gandhi CS, Papworth CG, Braman J, Shaughnessy MA, et al. A functionally defined model for the M2 proton channel of influenza A viru suggests a mechanism for its ion selectivity. Proc Natl Acad Sci USA 1997; 94: 11301-6.
56. Bauer CM, Pinto LH, Cross TA, Lamb RA. The influenza virus M2 ion channel protein: Probing the structure of the transmembrane domain in intact cells by using engineered disulfide cross-linking. Virology 1999; 254: 196-209.
57. Ito T, Gorman OT, Kawaoka Y, Bean WJ, Webster RG. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol 1991; 65: 5491-8.
58. Tang Y, Zaitseva F, Lamb RA, Pinto LH. The gate of the influenza virus M2 proton channel is formed by a single tryptophan residue. J Biol Chem 2002; 277: 39880-6.
59. Shuck K, Lamb RA, Pinto LH. Analysis of the pore structure of the influenza A virus M(2) ion channel by the substituted-cysteine accessibility method. J Virol 2000; 74: 7755-61.
60. Betakova T, Ciampor F, Hay AJ, Deakova E. The tryptophan 41 is not essential for the function of the M2 proton channel of influenza A virus. Options for the Control of Influenza V (Yoshihiro Kawaoka editor), Elsevier science BV 2004; 777-80.
61. Venkataraman P, Lamb RA, Pinto LH. Chemical rescue of histidine selectivity filter mutants of the M2 ion channel of influenza A virus. J Biol Chem 2005; 280: 21463-72.
62. Hu J, Fu R, Nishimura K, Zhang L, Zhou HX, Busath DD, et al. Histidines, heart of the hydrogen ion channel from influenza A virus: toward an understanding of conductance and proton selectivity. Proc Natl Acad Sci USA 2006; 103: 6865-70.
63. Salom D, Hill BR, Lear JD, DeGrado WF. pH-dependent tetramerization and amantadine binding of the transmembrane helix of M2 from the influenza A virus. Biochemistry 2000; 39: 14160-70.
64. Okada A, Miura T, Takeuchi H. Protonation of histidine and histidine-triptophan interaction in the activation of the M2 ion channel from influenza A virus. Biochemistry 2001; 40: 6053-60.
65. Nishimura K, Kim S, Zhang L, Cross TA. The closed state of a H+ channel helical bundle combining precise orientation and distance restraints from solid state NMR. Biochemistry 2002; 41: 13170-7.
66. Mecozzi S, West AP, Dogherty DA. Cation-pi interactions in aromatics of biological and medicinal interest: Electrostatic potential surfaces as a useful qualitative guide. Proc Acad Sci USA 1996; 93: 10566-71.
67. Betakova T, Ciampor F, Hay AJ. Influence of residue 44 on the activity of the M2 proton channel of influenza A virus. J Gen Virol 2005; 86: 181-4.
68. Gandhi CS, Shuck K, Lear JD, Dieckmann GR, DeGrado WF, Lamb RA, et al. Cu (II) inhibition of the proton translation machinery of the influenza A virus M2 protein. J Biol Chem 1999; 274: 5474-82.
69. Castrucci MR, Kawaoka Y. Reverse genetics system for generation of an influenza A virus mutant containing. a deletion of the carboxyl-terminal residue of M2 protein. J Virol 1995; 69: 2725-8.
70. Tobler K, Kelly ML, Pinto LH, Lamb RA. Effect of cytoplasmic tail truncations on the activity of the M(2) ion channel of influenza A virus. J Virol 1999; 73: 9695-701.
71. McCown M, Pekosz A. The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. J Virol 2005; 79: 3595-605.
72. Clader JW, Wang Y. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease. Curr Pharm Des 2005; 11(26): 3353-61.
73. Kido H, Okumura Y, Yamada H, Le TQ, Yano M. Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Curr Pharm Des 2007; 13(3): 403-12.
74. Tsai CH, Lee PY, Stollar V, Li ML. Antiviral therapy targeting viral polymerase. Curr Pharm Des 2006; 12(11): 1339-55.